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Summary: The aim of this study was to establish the concentration of insulin-like growth factor-I (IGF-I) in saliva
of acromegalic patients, and to compare it with the basal levels of serum IGF-I and growth hormone. IGF-I was
determined in extracted serum or neat saliva by a disequilibrium RIA using antibodies and iodinated ligand from
Amersham and WHO 87/518 s Standard. The detection limit of the assay was 0.5 μg/l, and the intra- and inter-
i ( assay coefficients of variations were 7.9% and 15% respectively. Our study included 13 healthy adult individuals
i t and 17 acromegalics. Compared with healthy adult subjects, acromegalics had significantly higher salivary IGF-I
i! concentrations (mean ± SEM 5.4 ± 2.64 vs. 10.5 +- 5.69 μg/l; p < 0.01), s well s serum IGF-I (176 ± 42.9 vs.
' * 520 ± 98.8 μg/l; p < 0.0001) and somatotropin levels (1.2 ± 1.02 vs. 15.4 ± 9.89 μg/l; p < 0.0001). However,
1
 47.1% patients (8 put of 17) with active acromegaly had salivary IGF-I concentrations within the normal r nge,
ί Serum IGF-I and somatotropin concentrations were found to follow more closely the disease activity after adeno-
j mectomy, compared with the concentrations of salivary IGF-I. These results suggest that the IGF-I levels in serum
and saliva are somatotropin-dependent. According to our results, measurement of IGF-I in saliva cannot be consid-
ered s an additional ineasure for evaluation of the disease activity in acromegaly, being less reliable than the
determination of IGF-I and somatotropin in serum.
Introduction dence that IGF-I is present in salivary glands of rats and
mice (6).
Circulating concentrations of IGF-I are dependent on the
rate of growth hormone (somatotropin) secretion, being The present study was undertaken to establish the value
low in hypopituitary and high in acromegalic patients (l, of IGF-I levels in the saliva of acromegalic patients and
2). Unlike insulin, IGF-I in the circulatioii (originatkg to compare it with serum IGF-I and somatotropin con-
mainly from liver), is bouad to specific binding proteins eentrations.
(3) and consequentially present in much higher coneen-
trations.
Patients and Methods
It has recently been reported (4, 5) that IGF-I in human
 p tients
mixed saliva is present in the free form only and that
i. codd * a good ««sure for pr««^ fte overaH
somatotropin Status. Unlike lipophilic 'drugs or steroid males, aged 29-62 years, were admitted for examination and
hormones, which are plasma ultrafdtrates, it is assumed studied after fiilly infonned oral consent had been obtained. All
*t_ ^ ^ τκ-,τ- ,· j · -i r> , ,· acromegalic patients had elevated basal somatotropin concentra-
that the IGFs m saliva are denved from the sahvaiy
 tions ^ were not suppressed below 5 μδΛ by an oral load of
glands (4, 5). There is also immunohistochemical evi- lOOgofglucose. An indwelling teflon cannula was inserted tnme
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antecubital vein after overnight fasting at 8 a. m., and two basal
blood samples vvere obtained at 8.30 and 9 a. m.; after clotting, the
blood was centrifuged at 1500g, and the serum was kept frozen at
-20 °C until analysed. Free flowing mixed saliva (5 ml) was then
collected during a 30-min period, centrifuged for 10 rnin at 1500g
at room temperatiire, and stored at -20 °C until analysis. Before
RJA, thawed saliva was centrifuged again and a clear, non-viscous
sample was analysed. Some samples needed f rther centrifugation
to obtain a clear, non-viscous saliva.
Assays
Serum samples for IGF-I determination were extracted according
to the method of Daughaday et al. (7), with some modifications.
Briefly, 0.1 ml of serum were extracted with 0.4 ml acidic ethanol
(2 mol/1 HC1, volume fraction 0.125, in absolute ethanol). After
centrifugation, 0.2 ml of the supernatant were neutralized with 0.1
ml 0.684 mol/1 Tris. The mixture was centrifuged and 0.1 ml of
the supernatant was finally diluted with 0.4 ml 0.025 mol/1 phos-
phate buffer, pH 7.6, with l g/l gelatine and 0.2 l NaN3 (RIA
buffer). In order to establish a sensitive and reliable method for
IGF-I determination in serum and saliva, RIA was optimized with
commercially available antibodies and iodinated ligand from Am-
ersham International (UK), using a disequilibrium assay: 0. l ml of
l : 37.5 diluted serum extract, pure mixed saliva or Standard (WHO
87/518) was.incubated with 0.1 ml of antibody solution (initial
dilution of l \ 6400 in RIA buffer) at 4 °C for 24 h. After incuba-
tion, 0. l ml of iodinated IGF-I was added and the tubes were f r-
ther incubated overnight for 16—18 h at 4 °C. Separation of the
bound and free ligand was performed with 0.8 ml of cold (4 °C)
200 g/l PEG 6000 in 0.025 mol/1 phosphate buffer, pH 7.2, contain-
ing 0.2 g/l NaN3, and centrifuged for 30 min, 3000 g at 4 °C. This
method of Separation was comparable with a more tedious one
using dextran coated charcoal, s described by the manufacturer,
giving non-specific binding of about 5%.
According to the manufacturer's data, cross reactivities of IGF-I
antibodies with IGF-II and insulin s well s epidermal growth
factor are negligible: crossreactivity with human IGF-II was
< 0.5%, a 50% displacement of ligand gave the insulin concentra-
tion of 2000 mU/1, and 95.2 μg/l of epidermal growth factor did
not differ from the Standard zero value. Intra-assay coefficients of
Variation (CVs) for serum concentrations at 101, 273 and 540 μg/l
(n = 20) were 6.4%, 4.0% and 5.7%, and for salivary concentra-
tions at 2.99, 5.93 and 13.7 μg/l (n = 20) they were 7.9%, 5.3%
and 6.7%, respectively. Interassay CVs for the same serum levels
(n = 9) were 9.3%, 8.5% and 8.9%, and for salivary levels (n = 7)
15.0%, 10.2% and 9.9%, respectively. The Standard curve covered
the r nge 0.48-62 μg/l? with an assay detection limit of 0.5 μ§/1.
The addition test, in which IGF-I Standard was added to serum or
saliva, and the dilution test in which serum was diluted with saline
and saliva with RIA buffer, produced lines that were parallel to the
Standard curve. With this System, both serum (after extraction) and
salivary IGF-I concentrations can be determined with the same
RIA. Growth hormone was determined with a commercially avail-
able RIA test manufactured by Diagnostic Products Corporation
(CA, USA). The test is calibrated against WHO 66/217, WHO 80/
505 and National Institutes of Health (NIH), NIAMDD-hGH-RP-
1. The assay detection limit was 0.5 μ§/1, and the intra- and inter-
assay CVs were 6.9% and 8.4%, respectively.
The results of hormone determinations represent the rnean of dupli-
cate determinations in blood collected at 9 a. m., or in mixed saliva.
Statistical analysis
For testing the between-group comparisons, Studenfs t test and t-
paired test were used s appropriate. Pearson's r was used for the
analysis of correlation. Statistical significanee of a two-tailed test
for less than 0.05 was considered significant. All values are ex-
pressed s mean ± SEM. Statgraphics 4.2 Software was used for
Statistical analysis on an IBM compatible Computer.
Results
With onr System, no detectable IGF-I eoncentrations
could be demonstrated in the presence of biadmg pro-
teins (e. g. serum), but we were able measure IGF-I con-
centrations in extracted serum pr neat saliva. Recovery
of 125I-labelled IGF-I added to serum was 99.9%
± 2.4% for normal, and 98.3% i 2.4% for acromegalic
sera. Multiple centrifugations of saliva did not ffect sal-
ivary IGF-I concentrations. Salivary IGF*I concentra*
tions showed a marked Variation when determined in
three acromegalics orice monthly during three consecu^·
tive months: saliva values ranged from 2.3 to 26.9 μ§/1,
in contrast to serum values, which varied from 559.7 to
619.6 μβ/1.
The patients with active acromegaly had significantly
higher salivary and serum IGF-I concentrations than the
normals: 10.5 ± 5.69 vs. 5.4 ± 2.64 μg/l (p < 0.01) and
520 ± 98.8 vs. 176 ± 42.9 μ§/1 (ρ < 0.0001), respec-
tively, s well s serum somatotropin concentrations:
15.4 ± 9.89 vs. 1.2 ± 1.02 μg/l (p < 0.0001). However,
eight out of 17 (47.1%) active acromegalics had salivary
IGF-I levels within the reference r nge. None of the
active acromegalics had serum IGF-I or somatotropin
within the reference r nge (fig. 1).
In the group of healthy individuals and those with acro-
megaly, no significant correlation between salivary IGF-
I and serum IGF4 or somatotropin was found. Neverthe-
less, in the combined group of healthy s bjects and
active acromegalics (n = 30), a significant correlation
between serum and salivary IGF-I was observed:
r = 0.489, p < 0.01; rto correlation between salivary
IGF-I and basal serum somatotropin concentrations
was found.
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Fig. l Concentrations of salivary and serum insulin-like growth
factor-I and serurn somatotropin in patients with active acromegaly
(A) and in healthy control individuals (C). The dashed line desig-
nates the upper limit of the values found in healthy s bjects (con-
trols). Acromegalics vs. controls: salivary IGF-I (p < 0.01); serum
IGF-I and somatotropin (p < 0.0001$.
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In five acromegalic patients before and after complete
adenomectomy, serum IGF-I and somatotropin concen-
trations differed significantly (p < 0.005), in contrast to
salivary IGF-I levels (p > 0.2) (tab. 1). Beside normal
preoperative levels of salivary IGF-I, there was also a
case of paradoxically increased salivary IGF-I concen-
tration postoperatively.
Discussion
A sensitive RIA test for the determination of IGF-I con-
centrations in serum (after extraction) and saliva was
designed. Within the same assay, serum and salivary
IGF-I could be determined, making the evaluation of
IGF-I levels in both samples more convenient.
Our results showed acromegalics to have significantly
higher mean serum IGF-I and somatotropin concentra-
tions and higher salivary IGF-I levels than the normal
subjects. However, salivary IGF-I showed poor correla-
tion with the disease activity; it was within the normal
ränge in almost a half of the active acromegalics. Some
patients had paradoxically low levels of salivary IGF-I,
although they showed clear signs of disease activity,
while serum IGF-I and somatotropin concentrations
were well above the normal ränge. None of the active
acromegalics had serum IGF-I or somatotropin concen-
tration within the normal ränge. Measurerhent of sali-
Tab. l Hormone concentrations ( §/1) before and after adeno-
mectomy for five patients with acromegaly (2—4 weeks postopera-
tively).
Hormone Preoperative Postoperative
Mean ± SEM Mean ± SEM
Salivary IGF-I
Serum IGF-I
Serum somatotropin
8.7 ± 1.40
450 ± 34.9
9.7 ± 1.48
7.3 ± 0.96
188 ± 23.4
0.26 ± 0.04
>0.2
<0.05
<0.05
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